Therini Bio raises additional $39 million Series A financing

16 May 2025

US clinical-stage biotech Therini Bio yesterday revealed that it raised $39 million in a Series A extension financing, which increased the company’s Series A total to $75 million.

The extension financing included new investors, Angelini Ventures and Apollo Health Ventures, in addition to existing investors SV Health Investors’ Biotech Fund and Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, Eli Lilly (NYSE: LLY), Dolby Family Ventures and Foundation for a Better World. This financing increased Therini Bio’s

Therini said it anticipates using the proceeds to fund Phase Ib trials evaluating its lead candidate, THN391, for the treatment of Alzheimer’s disease (AD) and diabetic macular edema (DME), as well as support development of a fibrin/VEGF bispecific.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK